Key Insights

Highlights

Success Rate

70% trial completion

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 49/100

Termination Rate

13.6%

3 terminated out of 22 trials

Success Rate

70.0%

-16.5% vs benchmark

Late-Stage Pipeline

18%

4 trials in Phase 3/4

Results Transparency

57%

4 of 7 completed with results

Key Signals

4 with results70% success

Data Visualizations

Phase Distribution

17Total
Not Applicable (10)
Early P 1 (1)
P 2 (2)
P 3 (3)
P 4 (1)

Trial Status

Completed7
Recruiting4
Unknown3
Terminated3
Active Not Recruiting3
Not Yet Recruiting2

Trial Success Rate

70.0%

Benchmark: 86.5%

Based on 7 completed trials

Clinical Trials (22)

Showing 20 of 20 trials
NCT06856850Recruiting

Disease Biosignatures in ALS/FTD Spectrum: New Impactful Biological Perspectives Beyond Clinical Approaches

NCT03096743Not ApplicableActive Not RecruitingPrimary

Evaluating Raised Intracranial Pressure Using MR Elastography

NCT06027567Phase 4CompletedPrimary

The Effect of an Anti-obesity Drug, Semaglutide, as Treatment in New-onset Idiopathic Intracranial Hypertension (IIH) Compared to Standard Weight Management (Dietician) With Regards to Change in Weight and Intracranial Pressure

NCT05762367Not ApplicableCompletedPrimary

MR Lymphatic Imaging in Idiopathic Intracranial Hypertention

NCT06855342RecruitingPrimary

Prospective Ocular Imaging for Intracranial Pressure Evaluation

NCT02896452Active Not Recruiting

Astronaut Vision Issues in a Ground Analog Population: Polycystic Ovary Syndrome

NCT06545981RecruitingPrimary

Ocular Perfusion in Patients With Idiopathic Intracranial Hypertension

NCT06436820Not Yet Recruiting

ICP & Outflow Study

NCT06059703Not ApplicableRecruitingPrimary

Biomarkers in the Etiology of Idiopathic Intracranial Hypertension

NCT05347147Phase 3TerminatedPrimary

A Trial to Determine the Efficacy and Safety of Presendin in IIH

NCT06361823Phase 3Not Yet RecruitingPrimary

Exploratory Study on the Efficacy and Safety of Semaglutide for Idiopathic Intracranial Hypertension Treatment

NCT03556085Not ApplicableActive Not RecruitingPrimary

Venous Sinus Stenting With the River Stent in IIH

NCT04314128Not ApplicableCompletedPrimary

Assessment of ICP in Idiopathic Intracranial Hypertension Using Transocular Ultrasound and Transcranial Doppler

NCT03501966Phase 3TerminatedPrimary

Surgical Idiopathic Intracranial Hypertension Treatment Trial

NCT05308823Not ApplicableUnknownPrimary

Outcome of Cerebral Venous Sinuses Stenting on Idiopathic Intracranial Hypertension

NCT02017444Phase 2CompletedPrimary

Safety and Effectiveness of 11b-Hydroxysteroid Dehydrogenase Type 1 Inhibitor (AZD4017) to Treat Idiopathic Intracranial Hypertension.

NCT02124486Not ApplicableUnknownPrimary

An RCT of Bariatric Surgery vs a Community Weight Loss Programme for the Sustained Treatment of IIH

NCT03867461Not ApplicableCompletedPrimary

The Effects of MAP and EtCO2 on Venous Sinus Pressures

NCT03963336Early Phase 1CompletedPrimary

Quantitative D-dimer Level and Anticoagulant Therapy in Idiopathic Intracranial Hypertension

NCT01003639Phase 2CompletedPrimary

Idiopathic Intracranial Hypertension Treatment Trial

Scroll to load more

Research Network

Activity Timeline